Trials / Completed
CompletedNCT04664153
Study To Assess Efficacy, Safety, Tolerability And Pharmacokinetics Of PF-07038124 Ointment In Participants With Atopic Dermatitis Or Plaque Psoriasis
A PHASE 2A, RANDOMIZED, DOUBLE BLIND, VEHICLE CONTROLLED, PARALLEL GROUP STUDY TO ASSESS THE EFFICACY, SAFETY, TOLERABILITY AND PHARMACOKINETICS OF PF-07038124 OINTMENT FOR 6 WEEKS IN PARTICIPANTS WITH MILD TO MODERATE ATOPIC DERMATITIS OR PLAQUE PSORIASIS
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 104 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This study is being conducted to provide data on efficacy, safety, tolerability and PK of PF-07038124 ointment versus vehicle control in the treatment of mild to moderate AD and mild to moderate plaque psoriasis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PF-07038124 ointment | PF-07038124 ointment at 0.01% with QD dosing for 6 weeks |
| DRUG | Vehicle ointment | Vehicle ointment with QD dosing for 6 weeks |
Timeline
- Start date
- 2020-12-21
- Primary completion
- 2021-08-18
- Completion
- 2021-08-18
- First posted
- 2020-12-11
- Last updated
- 2022-08-26
- Results posted
- 2022-08-26
Locations
29 sites across 4 countries: United States, Australia, Canada, Poland
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04664153. Inclusion in this directory is not an endorsement.